PTPRD
PTPRD (Receptor-type tyrosine-protein phosphatase delta) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Oesophageal cancer, Non-Hodgkin lymphoma and 5 more.
Overview
Can bidirectionally induce pre- and post-synaptic differentiation of neurons by mediating interaction with IL1RAP and IL1RAPL1 trans-synaptically. Involved in pre-synaptic differentiation through interaction with SLITRK2.
CIViC holds 4 clinical evidence items and 0 assertions across 5 variants, naming Temsirolimus, IGF1R Monoclonal Antibody, JSI-124 and Teprotumumab and others. IntOGen calls it a driver in 12 cohorts (8 activating, 4 loss-of-function), covering Invasive Breast Carcinoma, Oesophagogastric Adenocarcinoma, Oesophageal Adenocarcinoma, Oesophageal Squamous Cell Carcinoma, Lymphoid Neoplasm, Melanoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PTPRD (Receptor-type tyrosine-protein phosphatase delta) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Oesophageal cancer, Non-Hodgkin lymphoma and 5 more.
- 1 · What it is
PTPRD (Receptor-type tyrosine-protein phosphatase delta) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Oesophageal cancer, Non-Hodgkin lymphoma and 5 more.
- 2 · What goes wrong in cancer
Can bidirectionally induce pre- and post-synaptic differentiation of neurons by mediating interaction with IL1RAP and IL1RAPL1 trans-synaptically. Involved in pre-synaptic differentiation through interaction with SLITRK2.
- 3 · How drugs use it
No product in this corpus aims at PTPRD yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:9668 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P23468 (protein name, function text, keywords and locations (REST API)); CIViC gene PTPRD (4 evidence items, 0 assertions, 5 variants; diseases: Ewing Sarcoma, Head And Neck Carcinoma, Ewing Sarcoma Of Bone (GraphQL API, CC0)); IntOGen PTPRD (driver in 12 cohorts (Act 8, LoF 4); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Can bidirectionally induce pre- and post-synaptic differentiation of neurons by mediating interaction with IL1RAP and IL1RAPL1 trans-synaptically. Involved in pre-synaptic differentiation through interaction with SLITRK2. Location: Membrane (UniProt). Locus 9p24.1-p23 (HGNC).
- Breast cancer: IntOGen driver in 2 cohorts (BRCA)
- Oesophageal cancer: IntOGen driver in 2 cohorts (ESCA, ESCC)
- Non-Hodgkin lymphoma: IntOGen driver in 2 cohorts (LNM, NHL)
- Gastric & gastro-oesophageal junction cancer: IntOGen driver in 1 cohort (EGC)
- Ovarian cancer: IntOGen driver in 1 cohort (OVT)
- Pancreatic ductal adenocarcinoma: IntOGen driver in 1 cohort (PAAD)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 5 therapies; IntOGen calls it an activating (Act) driver in 8 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 4 cohorts; CIViC holds 4 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Head And Neck Carcinoma; Ewing Sarcoma Of Bone.
Latest papers
topQuery for this target: (TITLE:"PTPRD" OR ABSTRACT:"PTPRD" OR TITLE:"protein tyrosine phosphatase receptor type D" OR ABSTRACT:"protein tyrosine phosphatase receptor type D" OR TITLE:"Receptor-type tyrosine-protein phosphatase delta" OR ABSTRACT:"Receptor-type tyrosine-protein phosphatase delta") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PTPRD, not a curated reading list.
Similar pages
not linked directly; found by shared links- JournalJournal of gastrointestinal cancer
Shares Small intestine cancer (small bowel adenocarcinoma), Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.
- TargetCDKN1B
Shares Small intestine cancer (small bowel adenocarcinoma), Breast cancer (all types), CIViC, IntOGen.
- TargetCDKN2B
Shares Ewing sarcoma, Breast cancer (all types), CIViC, Pancreatic ductal adenocarcinoma.
- TargetSNX29
Shares Small intestine cancer (small bowel adenocarcinoma), IntOGen.
- TargetNUP214
Shares Small intestine cancer (small bowel adenocarcinoma), Non-Hodgkin lymphoma (all types), IntOGen.
- TargetSLFN11
Shares Ewing sarcoma, CIViC.
- TargetMAX
Shares Small intestine cancer (small bowel adenocarcinoma), Breast cancer (all types), IntOGen.
- CompanyActuate Therapeutics